PM Modi visits Bharat Biotech facility in Genome valley

Takes stock of the progress made by the Hyderabad-based company in the trials of Covaxin, jointly developed with ICMR-National Institute of Virology

Hyderabad: Prime Minister Narendra Modi visited Bharat Biotech facility at Genome Valley to review the Covid-19 vaccine development. The indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with the ICMR-National Institute of Virology. Covaxin has garnered interest from several countries worldwide for supplies and introduction.

Prime Minister Narendra Modi tweeted, “At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous Covid-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress.”

---

At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress. pic.twitter.com/C6kkfKQlbl

— Narendra Modi (@narendramodi) November 28, 2020

He interacted with Dr Krishna Ella, CMD, Suchitra Ella, Joint MD and Dr V Krishna Mohan, ED of Bharat Biotech and the scientists.

Bharat Biotech said, “We are humbled by the visit of Prime Minister Narendra Modi Ji to the Bharat Biotech manufacturing facility in Genome Valley, Hyderabad. Bharat Biotech is a leader in pandemic vaccines and we are truly honoured by this recognition. The prime minister’s visit serves as a great inspiration to our team, and further reinforces our commitment towards scientific discovery, solving public health issues, and the nation’s fight against Covid-19.”

Covaxin, India’s first indigenous vaccine with the Phase 3 clinical trial underway, is the first, largest, and the only efficacy trial in the developing world, involving a large number of volunteers across 25 sites.

The Phase III trial is being conducted across India in 26,000 participants. The vaccine will be produced in the only-of-its-kind Bio-Safety Level 3 production facility in the world.

“We take this opportunity to thank the Government of India, regulators, our vaccine development partners, medical fraternity, medical investigators including hospitals for their relentless assistance and cooperation in the development of vaccines, also Phase 3 clinical trials for Covaxin,” the company said.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

---